TapewireFind a company

person · Reporting owner

Byers Blake

Disclosed activity across 2 companies

Tapewire entity
126787
SEC CIK
0001741840

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813DirectorJune 05, 2020June 09, 2020
IonQ, Inc.IONQ · Entity 3350DirectorMay 26, 2022May 27, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date June 05, 2020 · Filed June 09, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.99 · Expires 2030-06-04Direct18,188 Reported balance After 2020-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-06-05 · Grant · Acquired 18,188 · Balance 18,188

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

IonQ, Inc.

Report date May 26, 2022 · Filed May 27, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect571,894 Reported balance After 2022-05-26 transaction · row 1
1 source row

Row 1 · 2022-05-26 · Grant · Acquired 16,210 · Balance 571,894

F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2032-05-26Direct32,050 Reported balance After 2022-05-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-05-26 · Grant · Acquired 32,050 · Balance 32,050

F2: The option will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

F2: The option will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 26, 2022 Filed May 27, 2022 17:19 UTC IonQ, Inc. IONQ · Entity 3350 GrantStock Option (right to buy) · Derivative 32,050 $0.00 Strike: $5.76 $0.00
Disclosure

SEC source: 0001209191-22-032655 · doc4.xml · derivative · entry 2

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,050

Underlying: Common Stock · 32,050 shares

Expires 2032-05-26

F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

Read SEC document
May 26, 2022 Filed May 27, 2022 17:19 UTC IonQ, Inc. IONQ · Entity 3350 GrantCommon Stock 16,210 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-032655 · doc4.xml · nonDerivative · entry 1

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 571,894

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2023 Annual Meeting (or the date immediately prior to the 2023 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting), or (ii) May 26, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.

Read SEC document
April 20, 2022 Filed Apr 22, 2022 18:43 UTC IonQ, Inc. IONQ · Entity 3350 OtherCommon Stock 125,967 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-025453 · doc4.xml · nonDerivative · entry 1

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 555,684

F1 · kind: Represents a pro rata distribution, and not a purchase of securities, from GV 2016 LP to the Reporting Person without additional consideration.

Read SEC document
April 11, 2022 Filed Apr 13, 2022 17:57 UTC IonQ, Inc. IONQ · Entity 3350 OtherCommon Stock 125,967 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-024325 · doc4.xml · nonDerivative · entry 1

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 429,717

F1 · kind: Represents a pro rata distribution, and not a purchase of securities, from GV 2016 LP to the Reporting Person without additional consideration.

Read SEC document
January 14, 2022 Filed Jan 19, 2022 18:13 UTC IonQ, Inc. IONQ · Entity 3350 GrantStock Option (right to buy) · Derivative 8,320 $0.00 Strike: $12.93 $0.00
Disclosure

SEC source: 0001209191-22-003797 · doc4.xml · derivative · entry 2

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,320

Underlying: Common Stock · 8,320 shares

Expires 2032-01-14

F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) the date of the 2022 Annual Meeting (or the date immediately prior to the 2022 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election), or (ii) January 14, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Director through such vesting date.

Read SEC document
January 14, 2022 Filed Jan 19, 2022 18:13 UTC IonQ, Inc. IONQ · Entity 3350 GrantCommon Stock 3,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-003797 · doc4.xml · nonDerivative · entry 1

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,750

F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on the earlier of (i) the date of the 2022 Annual Meeting (or the date immediately prior to the 2022 Annual Meeting if the Reporting Person's service as a director ends at such Annual Meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election), or (ii) January 14, 2023, subject in all cases to the Reporting Person's continued service as a member of the Board of Director through such vesting date.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 20:34 UTC IonQ, Inc. IONQ · Entity 3350 GrantCommon Stock 300,000 $10.00 $3,000,000.00
Disclosure

SEC source: 0001209191-21-059175 · doc4.xml · nonDerivative · entry 1

Byers Blake · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,000

F1 · shares: These shares were purchased from the Issuer in a private placement.

Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:30 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 18,188 $0.00 Strike: $9.99 $0.00
Disclosure

SEC source: 0000899243-20-015805 · doc4.xml · derivative · entry 1

BYERS BLAKE · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.

Read SEC document
June 07, 2019 Filed Jun 11, 2019 21:03 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 GrantStock Option (Right to Buy) · Derivative 18,188 $0.00 Strike: $13.40 $0.00
Disclosure

SEC source: 0000899243-19-016410 · doc4.xml · derivative · entry 1

BYERS BLAKE · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,188

Underlying: Common Stock · 18,188 shares

Expires 2029-06-06

F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:25 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries B Preferred Stock · Derivative 8,494,864 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018319 · doc4.xml · derivative · entry 3

BYERS BLAKE · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,287,511 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F1 · price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F1 · derivative.exercise_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F1 · derivative.expiration_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F2 · ownership.direct: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:25 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionSeries A Preferred Stock · Derivative 133,400 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018319 · doc4.xml · derivative · entry 2

BYERS BLAKE · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 51,626 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F1 · price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F1 · derivative.exercise_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F1 · derivative.expiration_date: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F2 · ownership.direct: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.

Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:25 UTC Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 ConversionCommon Stock 3,339,137 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-018319 · doc4.xml · nonDerivative · entry 1

BYERS BLAKE · CIK 0001741840 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,339,137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities converted into shares of the Issuer's common stock on a 2.58398:1 basis automatically immediately prior to the closing of the Issuer's initial public without payment of further consideration. The shares had no expiration date.

F2 · ownership.direct: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: The reported securities are directly held by GV 2016, L.P. GV 2016 GP, L.P., the general partner of GV 2016, L.P., GV 2016 GP, L.L.C., the general partner of GV 2016 GP, L.P., Alphabet Holdings LLC, the sole member of GV 2016 GP, L.L.C., XXVI Holdings Inc., the managing member of Alphabet Holdings LLC, and Alphabet Inc., the sole stockholder of XXVI Holdings Inc., may each be deemed to have sole power to vote or dispose of these shares. Dr. Byers is an affiliate of GV 2016 GP, L.P. but does not have voting or dispositive power over the shares held by GV 2016, L.P. Dr. Byers disclaims beneficial ownership of the shares held by GV 2016, L.P. except to the extent of his pecuniary interest, if any, therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purpose of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.